Navigation Links
Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief Executive Officer
Date:7/8/2008

HAYWARD, Calif., July 8 /PRNewswire/ -- Arete Therapeutics Inc., a privately-held biopharmaceutical company developing first-in-class soluble epoxide hydrolase (s-EH) inhibitors, today announced the appointment of James Sabry, M.D., Ph.D., as president and chief executive officer. Dr. Sabry has been a strategic advisor and member of the board of directors since March 2008. Dr. Sabry succeeds Dinesh Patel in the position of president and chief executive officer, who will remain as a consultant to the company.

"James brings a wealth of drug discovery, development, and biotechnology management expertise to Arete and already has made significant contributions to the company. We are confident that his exceptional entrepreneurial leadership will guide the company in the years to come as Arete continues to advance its pipeline of innovative compounds through clinical development," said James Topper, M.D., Ph.D., chairman of the board of Arete Therapeutics Inc. "In addition, on behalf of the board of directors, I would like to thank Dinesh Patel for his dedication and commitment to building a successful biotechnology organization while transitioning Arete from a discovery to a clinical stage company."

Dr. Sabry is chairman of the board of directors and former CEO of Cytokinetics, a company he co-founded in August 1997. Prior to co-founding Cytokinetics, he held faculty positions at the University of California, San Francisco and Harvard Medical School. He serves on the board of directors of HopeLab, a not-for-profit organization developing innovative technologies for the management of cancer, obesity and other diseases, is a member of Dean's Council of the Kennedy School of Government at Harvard University and serves on the advisory boards of numerous organizations including the California Institute of Quantitative Biosciences. Dr. Sabry received an M.D. from Queen's University and a Ph.D. in cell biology from the University of California, San Francisco.

"Arete Therapeutics is uniquely positioned to develop its pipeline of novel soluble epoxide hydrolase inhibitors for multiple disease indications and I look forward to applying my experience to build on the strong foundation and take the company to the next level of strategic and scientific excellence," said Dr. Sabry.

About Arete Therapeutics Inc.

Arete Therapeutics Inc. is a privately-held pharmaceutical company discovering and developing first-in-class small molecule drugs directed at soluble epoxide hydrolase (s-EH), a unique enzyme which plays a key role in the arachidonic acid pathway. Arete has discovered and developed a series of proprietary and chemically diverse molecules with preclinical efficacy in various animal models, and is conducting a phase 1 clinical trial with its first-in-class compound, AR9281. The company has raised a total of $51 million in Series A financing led by Frazier Healthcare Ventures, Alta Partners, Three Arch Partners, Burrill & Company and Altitude Life Science Ventures. For more information on Arete Therapeutics, please visit http://www.aretetherapeutics.com.


'/>"/>
SOURCE Arete Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking ... Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity as ...
Breaking Biology Technology:
(Date:6/1/2016)... -- Favorable Government Initiatives Coupled With Implementation ... to Boost Global Biometrics System Market Through 2021  ... " Global Biometrics Market By Type, By End ... - 2021", the global biometrics market is projected to ... growing security concerns across various end use sectors such ...
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
Breaking Biology News(10 mins):